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Crystal violet (CV) was used for several years in blood banks to eliminate the parasite Trypa-
nosoma cruzi in endemic areas in order to prevent transfusion-transmitted Chagas disease.
One mechanism of action described for CV involves inhibition of proline uptake. In T. cruzi,
proline is essential for host cell infection and intracellular differentiation among other pro-
cesses, and can be obtained through the proline permease TcAAAP069.
Methodology/Principal findings
CV inhibited proline transporter TcAAAP069 and parasites overexpressing this permease
were 47-fold more sensitive to this compound than control parasites. Using CV as reference
molecule, loratadine, cyproheptadine, olanzapine and clofazimine were identified as struc-
turally related compounds to CV (structural analogues) by in silico drug repurposing through
a similarity-based virtual screening protocol. All these already-approved drugs for clinical
use inhibited TcAAAP069 activity with different efficacies and also presented trypanocidal
action in epimastigotes, trypomastigotes and amastigotes of the Y, CL Brener and Dm28c
T. cruzi strains. Finally, a synergistic effect between benznidazole and the CV chemical ana-
logues was evidenced by combination and dose-reduction indexes values in epimastigotes
and trypomastigotes of the Y strain.
Conclusions/Significance
Loratadine, cyproheptadine and clofazimine inhibit TcAAAP069 proline transporter and also
present trypanocidal effect against all T. cruzi life stages in strains from three different
DTUs. These CV structural analogues could be a starting point to design therapeutic alter-
natives to treat Chagas disease by finding new indications for old drugs. This approach,
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called drug repurposing is a recommended strategy by the World Health Organization to
treat neglected diseases, like Chagas disease, and combination therapy may improve the
possibility of success of repositioned drugs.
Author summary
Chagas disease, caused by the parasite Trypanosoma cruzi, affects 7 million people world-
wide. Despite there are two drugs available since 50 years ago, the therapy presents severe
side effects and is not effective in the chronic phase of the disease when most of the
patients are diagnosed. Crystal violet (CV) was utilized as additive in blood banks to pre-
vent transfusion-transmitted Chagas disease. Proline is involved in many pathways, like
infection establishment and life cycle progression. In this work we first demonstrate that
CV has the proline permease TcAAAP069 as one of its molecular targets. Then we search
in a database of already-approved drugs for compounds that were structurally related to
CV under the premise “similar structure, similar activity”. We identified three drugs that
inhibit proline transport and present at least the same trypanocidal effect than benznida-
zole, the current treatment for Chagas disease. Finally we observed a synergistic effect
with the multidrug combined treatment. Drug discovery is an expensive and time-con-
suming process and Chagas disease is associated with poverty. The discovery of new indi-
cations to old drugs, called drug repurposing, can facilitate a rapid and more profitable
therapy application since preclinical trials and pharmacokinetic studies are already
available.
Introduction
Chagas disease is a neglected disease caused by the protozoan parasite Trypanosoma cruzi that
can be mainly acquired through an insect vector, blood transfusion, placental or congenital
transmission and consumption of contaminated food [1,2]. Among these mechanisms, blood
transfusion is still an important mechanism of transmission of Chagas disease due to lack of
blood bank control and migration of people from endemic to non-endemic countries [3,4].
However many non-endemic countries, like United States, United Kingdom, Spain and
France have already implemented screening of blood donations to prevent the transmission
[5]. Crystal violet (CV) is a well-known dye common in microbiology which was used for a
long time as an additive in blood banks in order to eliminate Chagas transmission in endemic
areas [6]. Different trypanocidal mechanisms have been proposed for CV, among them Hoff-
mann et al. demonstrated that proline and methionine transport were strongly inhibited by
this compound [7].
Chagas disease affects 7 million people in Latin America and almost 70 million more are at
risk of infection [8]. The only two approved drugs to treat this disease, benznidazole and nifur-
timox, were discovered over 50 years ago and present limited efficacy and several side effects
[9]. Thus the development of new therapies to treat Chagas disease remains as an urgent need.
The first multigenic family of amino acid transporters from T. cruzi (TcAAAP; Amino
Acid/Auxin Permeases; TC 2.A.18) was identified by our group [10]. Few members of this
family have been characterized in trypanosomatids, including the proline [11] (TcAAAP069),
arginine [12,13] (TcAAP3) and lysine [14] (TcAAP7) permeases. A polyamine transporter
[15,16] (TcPAT12) has also been characterized in T. cruzi and it probably belongs to the
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Amino Acid-Polyamine Organocation (APC; TC 2.A.3) family, which is phylogenetically very
close to the AAAP family. The transporter TcAAAP069 is mono-specific for D- and L-proline
and it is involved in resistance mechanisms to trypanocidal drugs and also to reactive oxygen
species including hydrogen peroxide and nitric oxide [11]. In addition, proline is a relevant
amino acid for trypanosomatids since it is used as an alternative carbon and energy source to
glucose [17]. It has been proved that in T. cruzi proline confers osmotic stress resistance [18]
and it also sustains cellular invasion in metacyclic trypomastigotes [19] as well as differentia-
tion of intracellular epimastigotes to trypomastigote forms, which is required for the establish-
ment of infection in mammalian hosts [20].
Orthologous genes of TcAAAP069 have been characterized in other trypanosomatids. In
Trypanosoma brucei, the orthologous permease TbAAT6 is a low-affinity low-selective trans-
porter for neutral amino acids, including proline [21]. The loss of TbAAT6 is enough to develop
resistance to eflornithine, a drug used to treat human African trypanosomiasis (HAT) [22].
Moreover, the importance of amino acid transporters in T. brucei has been demonstrated by
RNAi-mediated knock-down of arginine and lysine transporters TbAAT5-3 and TbAAT16-1
from the AAAP family which resulted in growth arrest in bloodstream forms [23]. In Leish-
mania donovani, the transporter LdAAP24 mediates proline and alanine uptake and regulates
the response to osmotic stress and amino acid homeostasis [24]. The parasite L. donovani natu-
rally expresses two variants of the proline/alanine transporter, one of them 18 amino acids
shorter than the other. While in T. cruzi no information is available about the determinants of
the substrate specificity of TcAAAP transporters, in LdAAP24 these 18 amino acids define
its substrate specificity for both amino acids (LdAAP24 long variant) or for proline alone
(Δ18LdAAP24 short variant) [25]. Recently, it has been reported that LdAAP24 also presents a
stage-specific expression and it is rapidly degraded when promastigotes are differentiated to
amastigotes [26]. TcAAAP069 activity and localization have been studied only in epimastigotes
overexpressing this proline permease [27], thus there is no information regarding stage-specific
expression.
Since the transporter TcAAAP069 has many differential features compared to those present
in mammals and proline is essential for parasite survival, it could be possible to design a spe-
cific TcAAAP069 inhibitor with trypanocidal action but non-toxic for the host cells. In fact, a
synthetic proline analogue named ITP-1G has been validated as a TcAAAP069 inhibitor
which also possesses trypanocidal effect [28]. One of the best strategies for the identification of
new treatments for neglected diseases is drug repositioning, which is the process of finding
new indications for existing drugs. The main benefit of this approach relays on those drugs
being ahead in the development and clinical phase I trials, consequently they could reach the
patients in approximately half of the time and with a significant lower cost [29]. Some success-
ful drugs repositioned for neglected diseases are eflornithine and miltefosine which were origi-
nally discovered for cancer therapy and now are used to treat HAT and leishmaniasis,
respectively [30]. Considering this information, in this work we performed an in silico screen-
ing of a drug database to find compounds structurally related to CV that could also inhibit
TcAAAP069 and exert trypanocidal effect but with less toxicity.
Methods
Parasites
Epimastigotes of Y, CL Brener and Dm28c strains (5 x106 cells/mL) were cultured at 28˚C in
plastic flasks (25 cm2), containing 5 mL of brain-heart infusion-tryptose (BHT) medium supple-
mented with 10% fetal calf serum (FCS), 100 U/mL penicillin, 100 μg/mL streptomycin and
20 μg/mL hemin [31]. VERO cells (5 x104 per well) were infected with trypomastigotes (2.5 ×105
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per well) for 4 h. After this period, the infected cells were washed twice with phosphate-buff-
ered saline (PBS), the MEM medium was replaced, and the cells were kept in culture at 37˚C,
5% CO2. In order to obtain intracellular amastigotes, the cells were lysed 4 days after infection
using a cell scraper, collected, washed twice with PBS (or MEM) and counted using a hemocy-
tometer. Trypomastigotes were obtained from infected VERO cells as previously described
[20].
Cells
VERO cells (African green monkey Kidney, ATCC CCL-81) were cultured in MEM medium
supplemented with 10% heat inactivated FCS, 0.15% (w/v) NaHCO3, 100 U/mL penicillin and
100 U/mL streptomycin at 37˚C in 5% CO2.
TcAAAP069 overexpressing parasites
The TcAAAP069 overexpressing parasites (Tc069) were available in our laboratory and were
previously characterized [28]. Briefly, TcAAAP069 (TriTrypDB ID: TcCLB.504069.120) was
amplified using genomic T. cruzi DNA as template. Amplification product was subcloned into
a modified pTREX expression plasmid called pTREXL (pTREX-069) [32,33]. Constructions
were transfected into T. cruzi epimastigotes of the Y strain as previously described [34]. Due to
the overexpression, the Tc069 parasites have about 9-fold increase in proline transport when
compared to wild type parasites [28].
Transport assays
Aliquots of epimastigote cultures (107 parasites) were centrifuged at 8,000 xg for 30 s, and
washed once with PBS. Cells were resuspended in 0.1 mL PBS and the assay started by the
addition of 0.1 mL of the transport mixture containing [3H]-proline (PerkinElmer’s NEN
Radiochemicals; 0.4 μCi) in the presence of 400 μM proline and different concentrations of the
indicated drug. Following incubation at 28˚C, reaction was stopped by adding 1 mL of ice-
cold PBS. Cells were centrifuged as indicated above, and washed twice with ice-cold PBS. Cell
pellets were resuspended in 0.2 mL of water and counted for radioactivity in UltimaGold XR
liquid scintillation cocktail (Packard Instrument Co., Meridien CT, USA) [35,36]. Cell viability
was assessed by direct microscopic examination and viability assays by using “Cell Titer 96
Aqueous One Solution Cell Proliferation Assay (MTS)” (Promega, Madison, WI, USA)
according to the manufacturer instructions. The loss of viability did not exceed 8% in any of
the transport assays. Non-specific uptake and carry over were assayed without incubation (T0),
or incubated at 4˚C. To evaluate if the effect of CV on proline uptake was related to the pres-
ence of Na+ or K+ ions, a transport assay was performed as described above using modified
PBS buffer (149.5 mM Na+ or K+) [37]. As a control, regular PBS buffer was used. To evaluate
if the effect of CV on proline uptake was related to the extracellular H+ concentration, the
transport was assayed on citrate buffer at different pH values (pH 5.0, 5.5, 6.0 and 6.5) [37].
Trypanocidal activity assays
Epimastigotes of T. cruzi were cultured as described above, in 24-wells plate at a start density
of 0.5 x107 cells/mL in BHT medium. Parasites´ growth was evaluated at different concentra-
tions of BZL, CV and CV structural analogues, and parasite proliferation was determined after
48 h. Trypanocidal activity in trypomastigotes and amastigotes was performed using 1 x106
cells/mL in 96-well plates and incubating at 37˚C for 24 h in the presence of the corresponding
drug. Growth was determined by counting in a Neubauer chamber and viability assays by
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using “Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (MTS)” (Promega,
Madison, WI, USA) according to the manufacturer’s instructions. Amastigotes were fixed with
methanol, stained and mounted with Vectashield with DAPI (Vector Laboratories, Burlin-
game, CA, USA), and then the non-lysed cells were counted by using fluorescence
microscopy.
Toxicity assays in VERO cells
The toxicity of the compounds was determined in VERO cells by the gentian violet staining
assay [38]. Briefly, the cells (1 x104 cells/well) were incubated in 96-well plates with the indi-
cated compound or dimethyl sulfoxide (DMSO) as negative control and maintained at 37˚ C
for 24 h. Then the cells were fixed for 15 min, and stained with 0.5% gentian violet. The absor-
bance was measured at 570 nm. The selectivity index (SI) was calculated for each CV analogue
as the ratio between the IC50 obtained in mammalian cells and the IC50 in trypomastigotes.
For the combined treatment, the results were presented as percentage of untreated cells.
Virtual screening
Similarity screening search was performed using the CV structure as reference (query) com-
pound (ZINC ID: 13763987). Structures (� 10,000) were obtained from the highly curated
“Sweetlead” database of world’s approved medicines, illegal drugs, and isolates from traditional
medicinal herbs [39]. The screening was performed using the softwares LiSiCA v1.0 [40]
(Ligand Similarity using Clique Algorithm), KCOMBU [41] (K(ch)emical structure COMpari-
son using the BUild-up algorithm), ShaEP [42] (Molecular Overlay Based on Shape and Elec-
trostatic Potential) v 1.1.2, and Shape-it v 1.0.1 [43] (Gaussian volumes as descriptor for
molecular shape). All these software were validated using control query structures (i.e. aspirin)
that were included into the database to verify that they were correctly identified by the used
algorithms and rated with the best score. Then, the screening with CV was performed.
Docking simulations and structural alignments
The homology model of TcAAAP069 was constructed using the I-TASSER-server [44] and
was based mainly on the structure of the Escherichia coli arginine/agmatine antiporter AdiC
(PDB ID: 3LRB), in addition to 9 templates of other proteins showing coverage between 0.72
and 0.95. The modeled structure had 93.7% residues in the residues in favored region of Rama-
chandran’s plot, and none of the residues located in non-allowed regions were involved in the
active site of the transporter. The model was refined using the software Modeller v7 [45]. Auto-
Dock 4.2.6 [46] was employed for docking assays, using a grid that covers the whole trans-
porter molecule to calculate the optimal energy conformations for the ligands interacting with
the residues within the permease cavity. The program was run using a Lamarckian Genetic
Algorithm 100 times, with a population size of 300, and 2.7 x104 as maximum number of gen-
erations. Structures alignments were performed using LigandScout 4.1.10 [47] (Inte:Ligand,
Software-Entwicklungs und Consulting GmbH, Austria) whose license was kindly granted to
our laboratory by the company. Modeling was performed using the LigandScout default
parameters.
Analysis of synergism
Calculations were performed using CompuSyn software (http://combosyn.com) which is
based on the median-effect equation [48] and its extension, the combination index [49].
Results are reported as Combination Index (CI), where CI< 1, CI = 1 and CI > 1 indicate
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synergism, additive effect and antagonism, respectively. LTD, CPH and CFZ were evaluated as
a single drug (LTD-CPH-CFZ) in combinations according to the following scheme: 1/2 IC50,
1/5 IC50, 1/10 IC50 and 1/25 IC50, for epimastigotes; and 1/3 IC50, 1/4 IC50, 1/5 IC50 and 1/10
IC50 for trypomastigotes, where IC50 refers to the value obtained for each one of the three CV
analogues. BZL was evaluated at the following concentrations: 20 μM, 10 μM, 5 μM, 1 μM and
0.1 μM, for epimastigotes; and 10 μM, 5 μM, 1 μM and 0.1 μM for trypomastigotes.
Statistics and data analysis
Kmapp and Vmax values were obtained by non-linear regression fit of the data to the Michae-
lis-Menten equation and IC50 values were obtained by non-linear regression of dose-response
logistic functions, using GraphPad Prism 6.01 for Windows. Synergism was evaluated using
the free software CompuSyn. All experiments were performed in triplicate and the results are
presented as mean ± standard deviation (SD).
Results
Effect of CV on the proline transporter TcAAAP069
In order to test if the previously reported decrease in proline transport by CV [7] is due to the
specific inhibition of the TcAAAP069 proline permease, the effect of CV on this transporter
activity was evaluated. After incubation with CV, doses that inhibit 50% of the proline trans-
port (IC50) were calculated for wild type (TcWT) and TcAAAP069 overexpressing (Tc069) T.
cruzi epimastigotes from Y strain [28]. The inhibitory effect of CV was significantly decreased
in Tc069 parasites with a calculated IC50 2.5-fold higher than control parasites (17.7 μM ± 1.1
and 7.1 μM ± 0.8, respectively; p<0.001) (Fig 1A). In addition, the mechanism of inhibition
was studied in TcWT parasites (S1 Fig). In absence of CV the kinetic parameters obtained for
proline transport were Kmapp = 0.663 mM ± 0.117 and Vmax = 157.3 pmol pro/min ± 29.0,
while the presence of CV did not alter the Vmax (Vmax = 148.3 pmol pro/min ± 24.2,
p = 0.701) but resulted in a significant augment of the Kmapp (Kmapp = 2.278 mM ± 0.409,
Fig 1. Validation of crystal violet as proline transporter TcAAAP069 inhibitor. (a) Inhibition of proline transport in wild type parasites (TcWT,
black circles) and parasites overexpressing TcAAAP069 (Tc069, white squares). (b) Trypanocidal effect of crystal violet in TcWT (black circles) and
Tc069 (white squares) parasites. The data is expressed as the mean ± standard deviation and corresponds to three independent experiments.
https://doi.org/10.1371/journal.pntd.0007481.g001
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p = 0.0028). These results indicate that CV acts on proline transporter with a reversible com-
petitive mechanism of inhibition.
Considering that the members of the TcAAAP transporter family are amino acid:H+ sym-
porters, the effect of extracellular ions was evaluated in the inhibition of proline transport by
CV. No differences were observed for proline transport and its inhibition in the absence of
Na+ or K+ cations (p = 0.8445, S2 Fig). Additionally, proline transport was measured at pHs
5.0, 5.5, 6.0 and 6.5 in presence or absence of CV to study the influence of H+. As previously
reported [50], the proline transport increases with the H+ concentration, but the addition of
CV did not alter the pH dependency (p = 0.0670, S2 Fig).
To further demonstrate that CV specifically interacts with TcAAAP069, the trypanocidal
effect of CV was evaluated using the same parasite models (TcWT and Tc069 cultures). The
toxicity of CV significantly increased when TcAAAP069 was overexpressed as evidenced by a
reduction in the IC50 value of 47-fold compared to wild type controls (0.27 μM ± 0.06 and
12.67 μM ± 2.1, respectively; p<0.0001) (Fig 1B). All these evidences suggest that proline trans-
porter TcAAAP069 is one of the targets of CV.
Similarity virtual screening
In order to identify chemical analogues of CV approved for human administration, the Sweet-
lead database was analyzed using four different algorithms that rank molecules according to
their similarity (LiSICA, ShaEP, KCOMBU and Shape-it). Compounds that complied with the
following criteria were selected: 1) being in the top five scored according to at least two differ-
ent algorithms; 2) have been used in humans, 3) sharing a substructure with CV by 3D align-
ment, and 4) being easily accessible in the pharmaceutical companies. Only four compounds
fitted all the established conditions; these drugs were loratadine (LTD; antihistamine), olanza-
pine (OLZ; antipsychotic), cyproheptadine (CPH; antihistamine) and clofazimine (CFZ; anti-
biotic). Dapsone (DPS; antibiotic) is an already-approved drug that shares some substructures
with CV, but since it was not in the top scored results it was designated as a control of the
selection strategy. The chemical structures of CV and its analogues are presented in the Fig 2.
It is worth mentioning that the resulting structure with the highest score obtained with the
four programs used was the CV itself, validating the scoring system of the algorithms used (S3
Fig). To identify the common chemical features between CV and the selected chemical ana-
logues, the LigandScout algorithm was used in order to perform feature-based structure align-
ments where the similarities are calculated as the number of matched feature pairs (MFP; i.e.
aromatic ring, hydrophobic area, hydrogen bond donor or acceptor, negative or positive ioniz-
able atom and metal binding location). The CV possesses eight features that were set as refer-
ences, which are four hydrophobic interactions, three aromatic rings and one positive
ionizable interaction. The chemical features shared between CV and its chemical analogues as
well as the alignments are schematized in the S3 Fig. The four CV analogues, CPH, LTD, CFZ
and OLZ, possess between 3 and 5 MFPs out of a total of 8 present in the CV. CPH is the com-
pound that shared more chemical features with CV; including two hydrophobic interactions,
two aromatic rings and one positive ionizable interaction.
Molecular docking of the TcAAAP069 inhibitors
The possible modes of interaction between LTD, CPH, OLZ, and CFZ with the proline trans-
porter TcAAAP069 were tested by a simulation with AutoDock 4.2.6, using proline and CV as
a reference of experimentally identified high affinity binders and to determine if the structure
similarity of the selected compounds and the CV translates into a similar mode of interaction
with the protein. To check if, as expected, there were not predicted interactions between the
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transporter and a molecule that does not comply with the selection criteria, a simulation with
DPS was also performed. According to the obtained docking models, proline, CV and the four
analogues bind different but close residues groups, located within the permease channel while
DPS does not appear to bind to any pocket in TcAAAP069 (Fig 3A and S4 Fig). The lowest
score values (ΔG) of the predicted interaction of proline and CV with the transporter are -4.07
and -5.26 kcal.mol-1, respectively. The binding scores of the four CV structural analogues were
lower than for proline and CV, with values between -9.60 kcal.mol-1 to -5.81 kcal.mol-1. This
suggests that CV and its chemical analogues form a more stable bond to that channel region of
TcAAAP069 than the natural ligand. All these data are summarized in Table 1.
The PRO site refers to the groove occupied by the proline pose, comprised by the sequential
group of residues 82–87 (GNVGSA), and the CV site refers to the pocket occupied by the CV
pose that includes the residues 264–265 (MM), 397–404 (SLIGALPA), 407 (M), and 462–474
(IMVVGTLSMVKGL) (Fig 3B). All the docked poses of CV analogues are located within the
CV site (S4 Fig). There is a "hot-spot" rich in A, M and V residues in the CV pocket, where the
hydrophobic rings of LTD, CPH, CFZ, and CV appear to converge. OLZ is not near this hot-
spot and it binds to the V and A residues of the PRO site, as well as to the residue I-399 of the
CV site. As mentioned, DPS predicted poses did not occupy any site inside the protein chan-
nel. All these results explain the most probable interaction between the CV, CV analogues and
TcAAAP069; however they were not taken as a criterion for the selection of the compounds to
be used in the subsequent in vitro tests.
Fig 2. Chemical structures of crystal violet, its analogues and negative control. The figure shows the chemical structure of crystal violet (a), the structure
of the negative control, dapsone, (b) and the structures of the four crystal violet structural analogues loratadine, cyproheptadine, olanzapine and clofazimine
(c).
https://doi.org/10.1371/journal.pntd.0007481.g002
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Inhibition of proline transport by CV chemical analogues
The four selected drugs that were structurally similar to CV and the negative control (DPS)
were tested as TcAAAP069 inhibitors. Preliminarily, proline transport assays were performed
using drug concentrations of 25 μM and 100 μM. All the CV analogues produced a significant
proline transport inhibition at both concentrations in epimastigotes, except for OLZ which
only inhibited proline transport at 100 μM (S5 Fig). DPS did not inhibit the proline transport
in any concentration assayed. Next, the concentration required to inhibit 50% of the proline
transport activity (IC50) was calculated for the four CV structural analogues. The IC50s
Fig 3. Binding poses suggested by molecular docking between proline, crystal violet and its chemical analogues with proline permease
TcAAAP069. (a) Homology modelled TcAAAP069 (represented as cartoon) highlighting the predicted interaction sites of proline (PRO site, green)
and crystal violet (CV site, violet; and dark shadowed-violet indicates the hydrophobic “hot-spot”). The predicted binding poses of proline (red), CV
(violet), loratadine (blue), cyproheptadine (yellow), olanzapine (dark-grey), clofazimine (green) and dapsone (pink) are shown in the figure. (b) Detail
of the residues predicted to interact with CV (right side) and proline (left side).
https://doi.org/10.1371/journal.pntd.0007481.g003









CFZ Clofazimine Lamprene 17953024 -9.60 -9.60
LTD Loratadine Alavert 537931 -8.01 -7.25
CPH Cyproheptadine Periactin 968264 -7.80 -7.76
OLZ Olanzapine ZyPREXA 52957434 -5.81 -5.34
CV Crystal Violet - 13763987 -5.26 -4.54
PRO Proline - 895360 -4.07 -3.60
DPS Dapsone Aczone 6310 -1.35 -1.08
All the drugs obtained by similarity-based screening, in addition to the reference compound (CV) and the natural substrate of TcAAAP069 (PRO), are listed in the table.
Columns indicate the compound abbreviation (Abbr.), the popular name and one of the brand names obtained from the website Drugs.com (https://www.drugs.com/),
the ZINC database ID, the lowest binding energy (ΔG all), and the lowest binding energy of the most populated cluster (ΔG MPC). Binding energy values were
calculated using the AutoDock software. Dash (-) instead of brand name indicates that the compound is marketed under its chemical (popular) name.
https://doi.org/10.1371/journal.pntd.0007481.t001
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obtained were 7.1 μM ± 0.8, 23.2 μM ± 3.8, 71.9 μM ± 11.2 and 4.3 μM ± 0.8 for CV, LTD,
CPH, and CFZ, respectively (Fig 4). It was not possible to calculate an IC50 for OLZ since this
compound produced the death of parasites in the lapse time of the assay in concentrations
over 300 μM.
Trypanocidal effect of CV structural analogues
Since the four CV analogues tested showed a significant inhibition of proline transport
through TcAAAP069 permease, all of them were also evaluated for trypanocidal activity on T.
cruzi epimastigotes. Although the IC50 of OLZ for proline transport inhibition could not be
calculated, it was included it in the trypanocidal activity assays because it produced the death
of parasites in the proline transport inhibition assay. Parasites were incubated with different
concentration of each compound during 48 h and the concentration required to inhibit 50%
of parasite growth (IC50) was calculated. All the compounds showed trypanocidal activity on
epimastigotes, being CFZ the compound with the lowest IC50 (9.3 μM ± 0.6) (Table 2 and S6
Fig). Moreover, CFZ presented a significantly lower IC50 than the control drug benznidazole
(BZL, p<0.001) while the other CV analogues, LTD, CPH and OLZ, were less effective than
Fig 4. Calculation of CV structural analogues concentrations required to inhibit 50% of proline transport activity
(IC50). The IC50s were calculated for three of the four CV analogues. It was not possible to calculate an IC50 for OLZ since
this compound produced the death of parasites in the lapse time of the assay in concentrations over 300 μM. The data is
expressed as the mean ± standard deviation and corresponds to three independent experiments. CV, crystal violet. LTD,
loratadine. CPH, cyproheptadine. OLZ, olanzapine. CFZ, clofazimine. N/A, not available.
https://doi.org/10.1371/journal.pntd.0007481.g004
Table 2. Trypanocidal effect of CV chemical analogues in T. cruzi Y strain.
Compound Epimastigotes Trypomastigotes Amastigotes Selectivity Index
Benznidazole 20.9 μM ± 1.4 14.9 μM ± 1.5 11.4 μM ± 0.5 >67
Crystal Violet 12.7 μM ± 2.1 0.4 μM ± 0.0 0.3 μM ± 0.1 -
Loratadine 26.4 μM ± 1.0 12.9 μM ± 0.8 13.2 μM ± 2.4 5.5
Cyproheptadine 52.6 μM ± 2.9 11.3 μM ± 0.6 10.7 μM ± 1.3 9.1
Olanzapine 120.5 μM ± 11.4 54.1 μM ± 2.9 N/A N/A
Clofazimine 9.3 μM ± 0.6 2.8 μM ± 0.1 1.1 μM ± 0.1 36.1
N/A: Data not available
https://doi.org/10.1371/journal.pntd.0007481.t002
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BZL (p<0.0001 for all of them). Subsequently, the drugs were tested on trypomastigotes, one
of the mammalian stages of T. cruzi, and all of them proved to have trypanocidal action. CFZ
was also the compound that presented the highest effect (2.8 μM ± 0.1) and, together with
CPH, showed an IC50 value significantly lower than BZL (p<0.0001 and p<0.01, respectively)
(Table 2 and S6 Fig). On the contrary, LTD presented a similar IC50 value than BZL while OLZ
was less effective (p<0.0001). In concordance with the proline transport inhibition assays,
OLZ was discarded for further studies due to its elevated IC50s (IC50 > 100 μM in epimasti-
gotes and IC50 > 50 μM in trypomastigotes). The remaining CV analogues were also evaluated
on amastigotes, the intracellular mammalian stage of T. cruzi, and all of them presented trypa-
nocidal effect with similar (LTD and CPH) or significantly lower IC50 values than BZL (CFZ,
1.1 μM ± 0.1, p<0.0001) (Table 2 and S6 Fig). Finally the toxicity of LTD, CPH and CFZ was
assessed in VERO cells in order to calculate the selectivity index (SI) and all the CV analogues
assayed were more selective to parasite cells with SI values between 5.5 and 36.1 (Table 2).
Altogether, the results indicate that CFZ is the only CV analogue tested that presents lower
IC50 values than BZL in all the T. cruzi stages assayed, while LTD and CPH have trypanocidal
activity against amastigotes and trypomastigotes with at least similar effect to BZL.
Trypanocidal effect of CV analogues on other strains
The results presented so far were obtained from T. cruzi parasites from Y strain (discrete typ-
ing unit–DTU–TcII). The trypanocidal action of LTD, CPH and CFZ was also evaluated on
epimastigotes of two other DTU strains, such as Dm28c (DTU TcI) and CL Brener (DTU
TcVI) since variations in trypanocidal treatment response have been reported for different T.
cruzi strains [51]. BZL and CV were assayed as well in order to compare the trypanocidal effect
between strains. The Y parasites were 1.6- and 1.3-fold more sensitive to BZL treatment than
Dm28c and CL Brener epimastigotes, respectively (p<0.0001, Table 3). Dm28c was 1.2-fold
more resistant to BZL than CL Brener (p<0.01). On the contrary, Dm28c and CL Brener para-
sites were more sensitive to CV than Y epimastigotes (p<0.0001). In addition, the results indi-
cate that the three CV chemical analogues are effective in other T. cruzi strains, including
DTUs of clinical relevance [52] (Table 3 and S7 Fig). Dm28c parasites were significantly more
sensitive to LTD and CPH treatments than the epimastigotes of Y (p<0.01 and p<0.0001,
respectively) and CL Brener strains (p<0.0001, for both drugs). However, no differences
between strains were observed in the treatment with CFZ, which was the only CV analogue
more efficient than BZL in epimastigotes of the three strains.
The trypanocidal effect of the CV analogues was also evaluated in trypomastigotes and
amastigotes of CL Brener and Dm28c strains at two concentrations, one of them around the
IC50 obtained in Y strain for the same stage (S8 Fig). In general, trypomastigotes of CL Brener
Table 3. Trypanocidal effect (IC50, μM) of CV structural analogues in epimastigotes from different strains of T. cruzi.
Compound T. cruzi strain
Y Dm28c CL Brener
Benznidazole 20.9 μM ± 1.4 32.5 μM ± 1.9 27.8 μM ± 1.8
Crystal Violet 12.7 μM ± 2.1 0.4 μM ± 0.0 3.2 μM ± 1.1
Loratadine 26.4 μM ± 1.0 21.0 μM ± 1.2 28.6 μM ± 2.0
Cyproheptadine 52.6 μM ± 2.9 37.6 μM ± 0.7 50.6 μM ± 2.2
Olanzapine 120.5 μM ± 11.4 N/A N/A
Clofazimine 9.3 μM ± 0.6 7.5 μM ± 0.8 9.0 μM ± 0.5
N/A, Data not available.
https://doi.org/10.1371/journal.pntd.0007481.t003
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strain were significantly more sensitive than parasites from the Y and Dm28c strains, which
presented a similar behavior, except for CV treatment. Regarding amastigotes, the response to
the different treatments was dependent of both drug and concentration, except for Dm28c
amastigotes treated with BZL that were consistently more resistant than CL Brener and Y
strains (p<0.01 for both strains, S9 Fig).
Synergism between CV structural analogues and benznidazole
The synergistic action between BZL and a combination of the CV analogues (LTD-CPH-CFZ)
was evaluated in T. cruzi epimastigotes from the Y strain. Drug interactions were classified
according to the combination index (CI) recognized as the standard measure of combination
effect based on the Chou-Talalay method [49]. CI< 1 means synergism, CI = 1 indicates addi-
tive effect, and CI > 1 is interpreted as antagonism. The combined administration of
LTD-CPH-CFZ and BZL produced a synergistic effect. The IC50 calculated for BZL single
treatment was 18.57 μM ± 1.07 and for the LTD-CPH-CFZ treatment was 18.05 μM ± 0.96. All
combinations between BZL and LTD-CPH-CFZ presented a CI< 1 with different synergism
degree, from strong to slight synergism (S10 Fig). The exceptions were the combination of 1/2
IC50 LTD-CPH-CFZ with 0.1 and 1 μM BZL, which presented a nearly additive effect and
moderate antagonism, respectively. The Chou-Talalay plot shows the CI and the effect (Fa,
fraction affected) produced by each combination point, where 0 means no effect and 1.0
means maximum trypanocidal effect (S10 Fig). Dose-reduction index (DRI) represents the
dose reduction that is allowed in combination for a given degree of effect as compared with
the dose of each drug alone. DRI > 1 indicates favorable dose-reduction. Except for the two
combinations that did not present a synergistic effect, the DRI values were higher than 1 for all
the combinations assayed with values between 2.5 and 374.2 for BZL and between 1.2 and 10.4
for LTD-CPH-CFZ (S1 Table). The combined treatment appeared to be more effective at
reducing BZL dose (up to two orders of magnitude) than the CV analogues concentrations,
since DRI values obtained for BZL were higher than those obtained for the LTD-CPH-CFZ
combination. Next, the multidrug treatment was evaluated in trypomastigotes. In this case, the
IC50 values calculated were 12.71 μM ± 1.53 and 8.78 μM ± 0.22 for BZL and LTD-CPH-CFZ
treatments, respectively. The combined treatment was also effective in trypomastigotes with
CI values between 0.29 and 0.87 indicating different degrees of synergism, from strong to slight
synergism (Fig 5A and Fig 5B). Only three combinations did not present synergism, with CI
values between 0.90 and 1.02 indicating nearly additive effect. The DRI values obtained were
higher than 1 for all the combination points assayed with values between 1.5 and 95.0 for BZL
and between 1.1 and 3.9 for LTD-CPH-CFZ (S2 Table). Finally, the multidrug treatment was
also evaluated in VERO cells (S3 Table). Since the highest combination tested in trypomasti-
gotes, 10 μM BZL with 10 μM LTD-CPH-CFZ, reduced the viability of VERO cells only by
11.2% ± 5.9, higher combinations were assayed and a maximum effect of 23.3% ± 2.9 was
observed with 100 μM BZL and 30 μM LTD-CPH-CFZ. Altogether, these results suggest that
combined treatment between BZL and the CV analogues could lead to reduced therapeutic
dosage and thus, to better tolerance to current treatments.
Discussion
New alternatives to current treatments against Chagas disease have been explored in the last
decade, including new trypanocidal drugs, such as the posaconazole, and the use of BZL in the
Chagas cardiomyopathy (BENEFIT trial) [53–56]. Unfortunately none of them were success-
ful, and there is still an urgent need for the development of new therapeutic substitutes for con-
ventional treatments. Drug repurposing or repositioning consist of finding new indications
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Fig 5. Synergism between benznidazole and the combination of the crystal violet analogues in T. cruzi trypomastigotes. (a) Drug combinations
between BZL and CV analogues (LTD-CPH-CFZ). Combination index (CI) value for each combination point is presented under the corresponding
graded symbol. Graded symbols mean strong synergism (++++, CI between 0.1–0.3), synergism (+++, CI between 0.3–0.7), moderate synergism (++, CI
between 0.7–0.85) and nearly additive effect (±, CI between 0.9–1.1). The boxes coloured with light-grey correspond to the combination points where no
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for drugs already approved for its use in humans. This approach is a recommended strategy by
the World Health Organization (WHO) to fight neglected diseases, like Chagas disease, since
costs and development time are significantly reduced for its application in therapy.
There are some recent examples of drug repositioning by virtual screening that use the T.
cruzi polyamine transporter TcPAT12 as main target; triclabendazole, an antiparasitic, sertaco-
nazole, a broad-spectrum antifungal, paroxetine, an antidepressant agent, isotretinoin, a well-
known medication used to treat severe acne, and cisapride, a gastroprokinetic agent. All these
compounds proved to be effective as TcPAT12 inhibitors that also have trypanocidal action
[57–59]. Regarding proline transport as therapeutic target, to our knowledge there are no pre-
vious reports of drug repositioning although some proline analogues have been studied as try-
panocidal compounds. For example, the proline analogue L-thiazolidine-4-carboxylic acid
(T4C) has been reported as a proline transporter inhibitor with trypanocidal effect [60], and
more recently, another proline analogue synthetized by rational design and called ITP-1G has
been validated as a TcAAAP069 inhibitor that also possesses trypanocidal activity [28].
Other compounds have been identified by drug repositioning as possible trypanocidal
drugs using different targets; such as the cruzipain [61–64], some T. cruzi kinases [65–67] and
the trans-sialidase [68], among other examples. Other drug repurposing approaches have
inferred the possible trypanocidal activity of already-approved drugs based on the reported
effect or mechanism of action of some compounds in other organisms [69–74].
In this work, a combined strategy involving similarity-based virtual screening followed by
in vitro assays was applied in order to obtain new trypanocidal compounds from a database
that contains already-approved drugs. CV was selected as a reference molecule since it has a
reported trypanocidal action and one of its mechanisms of action involved proline transport
inhibition [7]. The aim was to obtain structurally related compounds which may have similar
biological activity but with no (or less) toxicity toward the host cells since they are already in
use to treat human diseases. The proline transporter TcAAAP069 was selected as the probable
main target because: a) proline is a relevant amino acid for T. cruzi biology, including host cell
invasion and life cycle progression [19,20], b) TcAAAP069 mediates proline uptake and it can
also be used as a way of entry drugs into the parasite and, c) there is evidence of compounds
that inhibit TcAAAP069 and also have trypanocidal activity, like the proline analogues T4C
and ITP-1G [28,60].
First, proline transporter TcAAAP069 was evaluated as a possible target of CV in T. cruzi.
The ability of CV to inhibit proline uptake mediated through the permease TcAAAP069 was
evidenced by the 2.5-fold augment of the IC50 for the transporter activity and the 47-fold
reduction of the IC50 of trypanocidal effect in parasites overexpressing the transporter
TcAAAP069. CV inhibits the proline transport by a reversible competitive mechanism, and
this could be related with the predicted binding sites for CV and proline, which are close from
each other. Moreover, according to the molecular docking, CV analogues interact with the
same predicted residues of TcAAAP069 for CV hence they probably enter the cell like CV
through a reversible competitive mechanism. In addition, CV effect does not depend on extra-
cellular ions like Na+, K+ or H+. In accordance with previous results [50], proline transport
was independent of cations like Na+ or K+, and the addition of CV did not alter this behavior.
synergism was observed. (b) Chou-Talalay plot. Representation of CI vs effect (Fa, fraction affected), where CI> 1, CI = 1 (dotted line) and CI< 1
indicate antagonism, additive effect and synergism, respectively. For each data series BZL concentrations increase from left to right (from 0.5 to 10 μM).
The data is expressed as the mean ± standard deviation of three independent experiments. All calculations were performed with CompuSyn software.
LTD, loratadine. CPH, cyproheptadine. CFZ, clofazimine. BZL, benznidazole. IC50 LTD = 15 μM. IC50 CPH = 10 μM. IC50 CFZ = 5 μM.
LTD-CPH-CFZ, combination of the three crystal violet analogues as a single drug. 1/3 IC50, refers to the sum of 1/3 of each IC50, 5 μM + 3.67 μM + 1.33
μM = 10 μM. 1/4 IC50, 3.75 μM + 2.5 μM + 1.25 μM = 7.5 μM. 1/5 IC50, 3 μM + 2 μM + 1 μM = 6 μM. 1/10 IC50, 1.5 μM + 1 μM + 0.5 μM = 3 μM.
https://doi.org/10.1371/journal.pntd.0007481.g005
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Also, proline transport was dependent on extracellular H+ concentration, with higher activity
in the range of pH 5.0–5.5 and the presence of CV did not modify the pH dependency.
Once TcAAAP069 was validated as one of the targets of CV, the similarity-based virtual
screening was performed and four drugs already-approved for clinical use were obtained for
further analysis. All these CV chemical analogues retrieved by the virtual screening have
already been tested as antiparisitic agents in protozoans. LTD was evaluated in Leishmania (L.)
infantum as an antileishmanial compound and even though it presented an intermediate effect
on promastigotes it did not have effect on intracellular amastigotes [75]. CPH was assayed in
T. evansi in order to evaluate the ability of this compound to reverse drug resistance to some
trypanocidal drugs, like suramin, and the initial experiments showed the intrinsic toxic effect
of this compound [76]. OLZ was tested in Toxoplasma gondii due to the strong link demon-
strated between toxoplasmosis and psychiatric disorders but it presented a low anti-toxoplas-
mic activity [77]. Finally, CFZ was recently identified as a cruzipain inhibitor in T. cruzi with
trypanocidal action, but it was also reported that cruzipain is not the only target for this com-
pound [78].
LTD, CPH and CFZ were all able to inhibit proline transport and also proved to have trypa-
nocidal effect in epimastigotes, trypomastigotes and amastigotes of the parasite T. cruzi.
The IC50s obtained for these CV analogues were in the range of those reported with BZL in
epimastigotes for strains from different DTUs (IC50 values between 7–30 μM) [51]. Moreover,
the trypanocidal effect of CFZ was significantly higher than the observed with BZL in trypo-
mastigotes and amastigotes while the other two CV analogues showed at least similar effect to
the BZL. In contrast, OLZ presented an elevated IC50 both for epimastigotes and trypomasti-
gotes, and it was discarded for further analysis. The molecular docking predicted two hydro-
phobic sites inside the channel where CV and proline could stably bind to the transporter
TcAAAP069 and, interestingly, all the CV analogues clustered inside the TcAAAP069 channel,
mainly in the CV site as expected for structural analogues. These results could explain the
observed inhibition of proline transport by the CV structural analogues.
The fact that LTD, CPH and CFZ were also effective as trypanocidal compounds on epi-
mastigotes, trypomastigotes and amastigotes of CL Brener and Dm28c strains is interesting
because not all T. cruzi strains present the same response to current treatments [51], and even
drug resistance has been strain-associated [79]. Indeed there were differences on the treatment
response to BZL and CV between the three strains evaluated in this work. The response
observed to CV was particularly striking, with IC50 values 4.0- and 31.8-fold lower for CL
Brener and Dm28c epimastigotes, respectively, than the IC50 obtained for the Y strain. These
results indicate the importance of evaluate trypanocidal compounds in several strains in order
to prevent different and unexpected responses. Regarding the CV analogues, CFZ presented
the same effect on the three strains evaluated, while LTD and CPH proved to be significantly
more effective on Dm28c strain. The response in trypomastigotes and amastigotes was not
always in accordance to the observed in epimastigotes. For example Dm28c amastigotes were
more resistant to CFZ treatment than parasites from Y strain but trypomastigotes and epimas-
tigotes of both strains did not present differences. Regarding LTD and CPH, while Dm28c epi-
mastigotes were more sensitive to these drugs, only CL Brener trypomastigotes were more
susceptible to the treatment.
The combination of two or more drugs with different mechanisms of action is an alterna-
tive approach to increase the success rate of drug repositioning and, although multidrug ther-
apy may be difficult to implement, combination of drugs has been used to treat other
neglected diseases, for example the leprosy multidrug treatment recommended and supplied
by the WHO involves rifampicin, clofazimine and dapsone (MDT-COMBI). The combination
of already-approved drugs enables dosage reduction and diminishes toxicity, in addition to an
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improved efficacy and reduced drug resistance emergence. The final experiment herein pre-
sented showed positive interactions between the well-known drugs LTD, CPH and CFZ, and
BZL in epimastigotes and trypomastigotes of T. cruzi. In epimastigotes, most of the combina-
tion points of BZL with LTD-CPH-CFZ presented a synergistic effect, with CI values from
0.27 to 0.85 and DRI values from 2.5 to 374.2 for BZL and between 1.2 and 10.4 for LTD-
CPH-CFZ. For example, the combination of 1 μM BZL with 1/5 IC50 LTD-CPH-CFZ (17 μM,
CI = 0.70) produced an effect of 74% with 54-fold less BZL and 1.5-fold less LTD-CPH-CFZ
than each drug alone needed to achieve the same effect. In trypomastigotes, also most of the
combination points produced a synergistic effect between BZL and the CV analogues. For
example, an effect of 80% was achieved with the combination of 1 μM BZL and 1/4 IC50
LTD-CPH-CFZ (7.5 μM, CI = 0.65) which represents a 27-fold reduction of BZL dose and a
1.6-fold reduction of LTD-CPH-CFZ dose when compared to each drug alone needed to pro-
duce the same effect. These results suggest that the combination therapy would make possible
to diminish the dosage of BZL and thus, the toxicity and side effects reported [80]. However,
future studies will need to focus on whether this multidrug combination therapy can lead to
parasitological cures both in infected cells and mice.
The final goal would be to identify new treatments based on drug repositioning and/or
combination therapy that are more effective, better tolerated, and simpler to administrate than
current therapies for treating Chagas disease. Taking into account the urgent need for the
development of new drugs for Chagas disease, we can conclude that CV chemical analogues
could be a starting point to design therapeutic alternatives either alone or in combination with
BZL to treat this neglected disease.
Supporting information
S1 Fig. Effect of crystal violet in kinetic parameters of proline uptake. Kinetic analysis of
proline uptake was performed using different concentrations of proline (from 0 to 10 mM) in
the presence (+ CV) or absence of CV 5 μM (Control). The Lineweaver-Burk plot is showed as
an inset. The data is expressed as the mean ± standard deviation and corresponds to three
independent experiments. Data were fitted to the Michaelis-Menten equation using GraphPad
Prism 6 software.
(DOCX)
S2 Fig. Effect of extracellular ions in CV proline uptake inhibition. The assays were per-
formed in presence (+ CV) or absence of CV 10 μM (Control). a) Proline uptake was measured
in regular PBS or PBS containing only K+ (Na+ free buffer) or Na+ (K+ free buffer). b) Proline
uptake was measured in citrate buffer at pHs 5.0, 5.5, 6.0 and 6.5. Statistical analysis was per-
formed considering the transport at pH 5.0 as 100% for each treatment (Control and + CV)
and then the curves were adjusted to a linear regression in order to compare the slopes. The
data is expressed as the mean ± standard deviation and corresponds to three independent
experiments.
(DOCX)
S3 Fig. Chemical features shared between crystal violet and the selected compounds. The
LigandScout software was used to identify the common chemical features between crystal vio-
let (CV) and its chemical analogues. This algorithm performs feature-based structure align-
ments where the similarities are calculated as the number of matched feature pairs (MFP). (a)
In order to perform the structure comparisons, the 8 CV features were set as references. (b)
The LigandScout similarity score, the number of MFP obtained for each compound is listed
and the root mean square (RMS) of their positions is included. (c) The features shared between
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CV and each compound are shown and the structure alignments with the van der Waals sur-
faces are schematized. N/A, not available. AR, aromatic ring (purple circles). H, hydrophobic
area (yellow remarks). PI, positive ionizable atom (purple lines).
(DOCX)
S4 Fig. I. Predicted transmembrane spans of proline permease TcAAAP069. Transmem-
brane spans were predicted with TOPCONS software (http://topcons.cbr.su.se) and are num-
bered from 1 to 11. II. Predicted poses by molecular docking of the crystal violet structural
analogues and the proline permease TcAAAP069. Residues corresponding to the PRO and
CV sites in TcAAAP069 are indicated in green and violet, respectively. Detail of the
TcAAAP069 residues predicted to interact with (a) clofazimine, (b) loratadine, (c) cyprohepta-
dine and (d) olanzapine.
(DOCX)
S5 Fig. Inhibition of proline transport by crystal violet chemical analogues in wild type
parasites (TcWT). The crystal violet analogues and dapsone were evaluated as potential pro-
line transport inhibitors at two concentrations, 25 and 100 μM. Control, no treatment. The
data is expressed as the mean ± standard deviation and corresponds to three independent
experiments. DPS, dapsone. LTD, loratadine. CPH, cyproheptadine. OLZ, olanzapine. CFZ,
clofazimine. �, p< 0.05; ���, p< 0.001; ����, p<0.0001. ns, not significant.
(DOCX)
S6 Fig. Trypanocidal effect of CV structural analogues in (a) epimastigotes, (b) trypomas-
tigotes and (c) amastigotes of T. cruzi Y strain. The concentrations required to inhibit 50%
of parasite growth or parasite survival were calculated for the four CV chemical analogues. The
data is expressed as the mean ± standard deviation and corresponds to three independent
experiments. BZL, benznidazole. CV, crystal violet. LTD, loratadine. CPH, cyproheptadine.
OLZ, olanzapine. CFZ, clofazimine. N/A, not available.
(DOCX)
S7 Fig. Trypanocidal effect of CV structural analogues concentrations in epimastigotes of
(a) T. cruzi Dm28c and (b) CL Brener strains. The concentrations required to inhibit 50% of
parasite growth were calculated for three CV chemical analogues. OLZ was not tested in these
strains because of the high IC50s values obtained in trypomastigotes and epimastigotes of the Y
strain. The data is expressed as the mean ± standard deviation and corresponds to three inde-
pendent experiments. BZL, benznidazole. CV, crystal violet. LTD, loratadine. CPH, cyprohep-
tadine. OLZ, olanzapine. CFZ, clofazimine. N/A, not available.
(DOCX)
S8 Fig. Trypanocidal effect of CV structural analogues in trypomastigotes of T. cruzi
Dm28c and CL Brener strains. The trypomastigotes were treated with two concentrations of
each compound in order to compare the response of each strain. a) Benznidazole (BZL). b)
Crystal violet, (CV). c) Loratadine (LTD). d) Cyproheptadine (CPH). e) Clofazimine (CFZ).
The data is expressed as the mean ± standard deviation and corresponds to three independent
experiments. �, p<0.05. ��, p<0.01.
(DOCX)
S9 Fig. Trypanocidal effect of CV structural analogues in amastigotes of T. cruzi Dm28c
and CL Brener strains. The amastigotes were treated with two concentrations of each com-
pound in order to compare the response of each strain. a) Benznidazole (BZL). b) Crystal vio-
let, (CV). c) Loratadine (LTD). d) Cyproheptadine (CPH). e) Clofazimine (CFZ). The data is
expressed as the mean ± standard deviation and corresponds to three independent
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experiments. �, p<0.05. ��, p<0.01.
(DOCX)
S10 Fig. Synergism between benznidazole and the combination of the crystal violet ana-
logues in T. cruzi epimastigotes. (a) Drug combinations between BZL and CV analogues
(LTD-CPH-CFZ). Combination index (CI) value for each combination point is presented
under the corresponding graded symbol. Graded symbols mean strong synergism (++++, CI
between 0.1–0.3), synergism (+++, CI between 0.3–0.7), moderate synergism (++, CI between
0.7–0.85), nearly additive effect (±, CI between 0.9–1.1), and moderate antagonism (- -, CI
between 1.2–1.45) [81]. The boxes coloured with light-grey correspond to the combination
points where no synergism was observed. (b) Chou-Talalay plot. Representation of CI vs effect
(Fa, fraction affected), where CI > 1, CI = 1 (dotted line) and CI < 1 indicate antagonism,
additive effect and synergism, respectively. For each data series BZL concentrations increase
from left to right (from 0.1 to 20 μM). The data is expressed as the mean ± standard deviation
and corresponds to three independent experiments. All calculations were performed with
CompuSyn software. LTD, loratadine. CPH, cyproheptadine. CFZ, clofazimine. BZL, benzni-
dazole. IC50 LTD = 25 μM. IC50 CPH = 50 μM. IC50 CFZ = 10 μM. LTD-CPH-CFZ, combina-
tion of the three crystal violet analogues as a single drug. 1/2 IC50, refers to the sum of half of
each IC50, 12.5 μM + 25 μM + 5 μM = 42.5 μM. 1/5 IC50, 5 μM + 10 μM + 2 μM = 17 μM. 1/10
IC50, 2.5 μM + 5 μM + 1 μM = 8.5 μM. 1/25 IC50, 1 μM + 2 μM + 0.4 μM = 3.4 μM.
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